Q-omics provides the consensus-scored MIR7975 profile across patient tissues and cancer cell-line models. MIR7975 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR7975 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, MIR7975 RNA expression shows 7,995 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, HNSC, and TGCT as cancer lineages where MIR7975 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7975 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7975 survival associations across molecular data types. MIR7975 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7975 RNA expression–survival associations across cancer types. High MIR7975 expression shows unfavorable associations in SKCM, COAD, PAAD, BRCA, MESO and SARC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR7975 RNA expression.
This table summarizes MIR7975 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7975. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7975 shows lower tumor expression in HNSC. The HNSC box plot shows higher MIR7975 RNA expression in normal versus tumor tissue (log2 FC = −0.248, t-test p = .008).
This table shows molecular features associated with MIR7975 in patient tissues and cancer cell lines. In patient samples, MIR7975 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
